导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.68% | 1170/4773 |
| 近一周 | -0.78% | 1863/5467 |
| 近一月 | -6.27% | 3015/5421 |
| 近一季 | -9.30% | 2970/5238 |
| 近半年 | -1.26% | 1883/4931 |
| 近一年 | 9.87% | 1056/4400 |
| 近两年 | 81.63% | 812/2954 |
| 近三年 | 46.07% | 627/2253 |
| 成立以来 | -10.94% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.12% 1051/4961 |
19.45% 1296/5312 |
- - |
- - |
| 2025 | 33.31% 1122/4813 |
2.86% 1247/3635 |
2.30% 1667/4076 |
24.49% 1460/4524 |
1.77% 1225/4813 |
| 2024 | 8.86% 1511/3463 |
-2.68% 1406/2808 |
-4.96% 1601/3014 |
16.23% 1502/3129 |
1.26% 1095/3463 |
| 2023 | -6.15% 815/2656 |
7.45% 571/2280 |
-4.09% 1043/2385 |
-4.61% 1181/2515 |
-4.53% 1076/2655 |
| 2022 | -18.14% 668/2207 |
-13.32% 733/1919 |
2.90% 1240/2016 |
-10.42% 401/2113 |
2.44% 936/2208 |
| 2021 | 16.21% 274/1822 |
-1.04% 421/1255 |
9.28% 568/1330 |
4.16% 376/1466 |
3.16% 466/1822 |
| 2020 | 20.89% 701/1250 |
-4.04% 336/1028 |
15.79% 473/1067 |
5.84% 892/1164 |
2.79% 966/1184 |
| 2019 | 26.81% 563/1092 |
30.66% 235/739 |
-8.47% 592/788 |
0.10% 560/850 |
5.93% 666/918 |
| 2018 | -30.98% 485/834 |
- - |
-13.19% 434/631 |
-7.30% 444/660 |
-12.42% 443/682 |
| 2017 | 1.56% 450/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.72% 363/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国寿安保中证500ETF联接 VS. 长安沪深300非周期A(740101) |